FDA approves UroGen’s Zusduri to treat recurrent bladder cancer
Approximately 59,000 LG-IR-NMIBC patients experience recurrent disease every year in the US
Read More
Tag: bladder cancer
Therapy reprogrammes immune cells to shrink prostate and bladder cancers
JHU083 reduced tumour growth and triggered tumour cell death in mice
Read More
Study finds mechanical changes in tumour tissue offer new insights for cancer research
Bladder cancer, including papillary tumours, is the ninth most common cancer type worldwide
Read More
NICE overturns previous decision, recommends Merck and Pfizer’s Bavencio
Following successful appeals, the therapy has been recommended for all eligible bladder cancer patients
Read More
Nonacus partners with Birmingham University to develop bladder cancer test
Nonacus is aiming to launch the ‘highly sensitive’ non-invasive bladder cancer test within 12 months
Read More
Preliminary NICE ‘no’ for Merck’s Bavencio
The cost regulator has rejecting funding the drug as maintenance treatment of advanced/metastatic urothelial cancer
Read More
Gilead’s Trodelvy scores accelerated approval in advanced bladder cancer
US Food and Drug Administration approved antibody drug conjugate based on Phase II trial results
Read More
Roche withdraws US indication for Tecentriq in bladder cancer
Tecentriq failed to improve overall survival in post-marketing study
Read More
AZ withdraws Imfinzi indication in the US for advanced bladder cancer
Decision made in consultation with the FDA following disappointing trial results
Read More
UK bladder cancer patients get early access to Bavencio
UK MHRA has issued positive scientific opinion enabling the drug’s inclusion on the Early Access to Medicines Scheme
Read More
Priority review for Imfinzi’s less-frequent dosing regimen
AZ says approval would “simplify and improve treatment by enabling continuity of care while minimising the risk of exposure to infection in the healthcare setting”
Read More
US approves Bavencio for bladder cancer
In a clinical trial, Bavencio maintenance treatment extended median overall survival by 50% over standard of care
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
